#USA #Mumbai #Piramal Pharma #Botanix Pharmaceuticals #Sofdra

Piramal Pharma Solutions and Botanix: A New Era in Drug Development

Piramal Pharma Solutions (PPS), a key player in the global Contract Development and Manufacturing Organization (CDMO) sector, has proudly announced a partnership with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited. This strategic alliance aims to support the development and commercial supply of Sofdra®, an innovative treatment for primary axillary hyperhidrosis, which has earned the distinction of being the first and only FDA-approved new chemical entity (NCE) for this condition.

Understanding Sofdra®

Sofdra® represents a significant breakthrough for patients suffering from primary axillary hyperhidrosis, a medical condition that can heavily impact one's quality of life. With its FDA approval, it offers a new, safe, and effective solution for this socially challenging condition, presenting a new lease on life for many who have struggled with excessive sweating and the associated stigma.

Strong Manufacturing Backbone

As part of this partnership, Piramal Pharma Solutions will leverage the capabilities of its North American drug substance facilities to ensure a robust and consistent supply of Sofdra®. The Riverview, Michigan facility will initiate the development and validation services for Sofpironium Bromide, the active pharmaceutical ingredient (API) in Sofdra®. Following successful validation, they will also consider validating the production process at the Aurora, Canada facility. This dual-site approach not only enhances Botanix’s supply chain flexibility but also ensures that they can depend on PPS as a reliable commercial API supplier.

Advantages of a Dual-Site Strategy

This innovative twin-site strategy is poised to yield several advantages. First, it provides redundancy, continuity, and scheduling flexibility in the supply chain. In the face of geopolitical uncertainties, PPS can seamlessly switch production between these two sites, maintaining a steady supply for Botanix and ultimately its patients.

Moreover, this collaboration not only enhances logistical efficiency but also allows for financial benefits, effectively de-risking the supply chain for Botanix. Peter DeYoung, CEO of Piramal Global Pharma, emphasizes the importance of this partnership in delivering customized, resilient solutions designed to meet the specific needs of Botanix, reinforcing the commitment of PPS to patient-centric solutions.

Future Aspirations

This initial phase will pave the way for future supply needs of Sofpironium Bromide as PPS expands its capabilities to accommodate potential increases in demand. Through this proactive approach, PPS aims to support not just the current needs but also anticipate future requirements for Sofdra®, ensuring that patients reliant on this therapy maintain consistent access to their treatment.

As Piramal Pharma Solutions continues its commitment to improving the lives of patients impacted by hyperhidrosis, they remain dedicated to excellence and innovation in pharmaceutical solutions. The overarching goal of this partnership is to enhance patient quality of life, highlighting the importance of collaboration in pharmaceutical development.

About the Companies

Piramal Pharma Solutions operates across the entire drug life cycle, offering a wide range of services from drug discovery to commercial manufacturing. Their global network allows for seamless service delivery, ensuring top-tier quality and efficiency throughout.

Botanix Pharmaceuticals, on the other hand, has positioned itself as a leader in dermatology, focused on advancing treatment options that make a meaningful difference in patients' lives. With their flagship product approved, they are well on their way to redefining treatment paradigms in dermatological care.

Together, these organizations are set on a path of innovation that promises to make a significant impact on the treatment landscape for primary axillary hyperhidrosis and beyond.